BAY1834845
BAY1834845 is a pharmaceutical drug with 4 clinical trials. Historical success rate of 100.0%.
Success Metrics
Based on 4 completed trials
Phase Distribution
Phase Distribution
4
Early Stage
0
Mid Stage
0
Late Stage
Highest Phase Reached
Phase 1Trial Status & Enrollment
100.0%
4 of 4 finished
0.0%
0 ended early
0
trials recruiting
4
all time
Detailed Status
Development Timeline
Analytics
Development Status
Trials by Phase
Trials by Status
Recent Activity
A Trial to Learn How BAY1834845 and BAY1830839 Affect Inflammation When Taken by Mouth Twice a Day for 7 Days in a Row in Healthy Male Participants
A Multiple Dose Study of BAY1834845 in Healthy Male Subjects and in Patients With Psoriasis
Food Effect, Oral & Intravenous Pharmacokinetics and Absolute Bioavailability of BAY1834845 Including Drug-drug Interaction With Methotrexate
First in Human Study to Investigate the Safety, Tolerability, Pharmacokinetics and to Explore Pharmacodynamics of BAY1834845
Clinical Trials (4)
A Trial to Learn How BAY1834845 and BAY1830839 Affect Inflammation When Taken by Mouth Twice a Day for 7 Days in a Row in Healthy Male Participants
A Multiple Dose Study of BAY1834845 in Healthy Male Subjects and in Patients With Psoriasis
Food Effect, Oral & Intravenous Pharmacokinetics and Absolute Bioavailability of BAY1834845 Including Drug-drug Interaction With Methotrexate
First in Human Study to Investigate the Safety, Tolerability, Pharmacokinetics and to Explore Pharmacodynamics of BAY1834845
All 4 trials loaded
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 4